Essential Hypertension Clinical Trial
— OSCAROfficial title:
A Phase III, Multicenter, Open-Label, Dose-Titrating, 16-Week Study Evaluating The Efficacy, Tolerability and Safety of Olmesartan Medoxomil 20 Mg and 40 Mg Alone or in Combination With 12.5 Mg to 25 Mg of Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
| NCT number | NCT00139698 |
| Other study ID # | A0021002 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 3 |
| First received | |
| Last updated | |
| Start date | September 2005 |
| Est. completion date | July 2006 |
| Verified date | December 2018 |
| Source | Pfizer |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
| Status | Completed |
| Enrollment | 410 |
| Est. completion date | July 2006 |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 65 Years |
| Eligibility |
Inclusion Criteria: - Subject has mild to moderate hypertension Exclusion Criteria: - History of secondary hypertension |
| Country | Name | City | State |
|---|---|---|---|
| Pfizer Investigational Site | |||
| Colombia | Pfizer Investigational Site | Barranquilla | Atlantico |
| Colombia | Pfizer Investigational Site | Bogota | Cundinamarca |
| Colombia | Pfizer Investigational Site | Cali | Valle Del Cauca |
| Colombia | Pfizer Investigational Site | Cartagena | Atlantico |
| Colombia | Pfizer Investigational Site | Medellin | Antioquia |
| Ecuador | Pfizer Investigational Site | Escobedo | Guayas |
| Ecuador | Pfizer Investigational Site | Quito | Pichincha |
| Hong Kong | Pfizer Investigational Site | NT | |
| Hong Kong | Pfizer Investigational Site | Shatin, NT | |
| Indonesia | Pfizer Investigational Site | Jakarta | |
| Indonesia | Pfizer Investigational Site | Jakarta | |
| Indonesia | Pfizer Investigational Site | Jakarta | |
| Indonesia | Pfizer Investigational Site | Surabaya | |
| Malaysia | Pfizer Investigational Site | Kuching | Sarawak |
| Malaysia | Pfizer Investigational Site | Seremban | Negeri Sembilan |
| Philippines | Pfizer Investigational Site | Quezon | |
| Philippines | Pfizer Investigational Site | San Juan | Metro Manila |
| Singapore | Pfizer Investigational Site | Singapore | |
| Singapore | Pfizer Investigational Site | Singapore | |
| Taiwan | Pfizer Investigational Site | Guei-Shan Shiang | Tau-Yuan Shian |
| Taiwan | Pfizer Investigational Site | Kaohsiung | |
| Taiwan | Pfizer Investigational Site | Taipei | |
| Taiwan | Pfizer Investigational Site | Taipei | |
| Thailand | Pfizer Investigational Site | Bangkok | |
| Thailand | Pfizer Investigational Site | Bangkok | |
| Thailand | Pfizer Investigational Site | Chiang Mai | |
| Thailand | Pfizer Investigational Site | Khet Rajathevee | Bangkok |
| Turkey | Pfizer Investigational Site | Bornova/Izmir | |
| Turkey | Pfizer Investigational Site | Haseki/Istanbul | |
| Turkey | Pfizer Investigational Site | S¿hhiye/Ankara | |
| Turkey | Pfizer Investigational Site | Sihhiye/Ankara |
| Lead Sponsor | Collaborator |
|---|---|
| Pfizer |
Colombia, Ecuador, Hong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand, Turkey,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Efficacy of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension | |||
| Secondary | Safety and tolerability of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03708601 -
Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
|
||
| Not yet recruiting |
NCT05503953 -
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
|
Phase 3 | |
| Recruiting |
NCT05526703 -
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy
|
Phase 3 | |
| Completed |
NCT02890173 -
Study of CS-3150 in Patients With Essential Hypertension
|
Phase 3 | |
| Completed |
NCT02944734 -
Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension
|
Phase 2 | |
| Withdrawn |
NCT02096939 -
Microvascular Function in Primary Aldosteronism
|
N/A | |
| Recruiting |
NCT01956786 -
Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
|
Phase 2/Phase 3 | |
| Completed |
NCT02553512 -
Helius in Hypertension-I: The UK Hypertension Registry
|
N/A | |
| Completed |
NCT01198249 -
Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension
|
Phase 1 | |
| Completed |
NCT01001572 -
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
|
Phase 3 | |
| Recruiting |
NCT00380289 -
Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension
|
N/A | |
| Completed |
NCT00288184 -
Uric Acid in Essential Hypertension in Children
|
Phase 2 | |
| Completed |
NCT01289886 -
Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects
|
Phase 1 | |
| Not yet recruiting |
NCT06041529 -
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension
|
Phase 4 | |
| Completed |
NCT04470830 -
A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
|
||
| Completed |
NCT00758524 -
A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
|
Phase 2 | |
| Recruiting |
NCT05109013 -
Juvenile Essential Arterial Hypertension and Vascular Function
|
||
| Completed |
NCT00741585 -
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment
|
Phase 4 | |
| Active, not recruiting |
NCT05843682 -
Technological Innovation in the Virtual Assistance of Patients With Uncontrolled Arterial Hypertension - Hyper 2
|
N/A | |
| Recruiting |
NCT04554303 -
Comparing Safety and Efficacy of Amlodipine Verses S Amlodipine in Patients With Essential Hypertension
|